BridgeBio Pharma Inc vs Check Point Software Technologies Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Check Point Software Technologies Ltd trades at $129.48 (market cap $13.39B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | CHKP | |
|---|---|---|
Market Cap | $16.61B | $13.39B |
Sector | Health | Technology |
52-Week High | $90.17 | $206.91 |
52-Week Low | $47.29 | $112.47 |
Enterprise Value | $18.16B | $13.09B |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Check Point Software (CHKP) trades at $127.82, up 2.03% today, but remains in a bearish technical trend. The company maintains strong profitability with 37.93% net margins and has beaten earnings estimates for three consecutive quarters. Recent news includes insider selling by the CRO and recognition as a visionary leader in enterprise risk management platforms. Technical indicators show oversold conditions with RSI at 24.45, suggesting potential for near-term bounce.
CHKP presents a value opportunity with attractive P/E of 13.45, trading below analyst consensus target of $146.92. However, structural challenges in hardware demand and margin compression create headwinds. The stock's 36% decline year-to-date may have created a buying opportunity for patient investors, though near-term volatility is expected given bearish technical signals and mixed analyst sentiment.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →